We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Magnetic Test Developed For Cholera Toxin

By LabMedica International staff writers
Posted on 03 Mar 2011
A test has been developed than can detect the toxin of the bacterium Vibrio cholerae, the causative agent of cholera. More...


A molecular mimicry strategy can used to identify targeting ligands that bind to the cholera toxin B subunit (CTB) that can be found in blood, water or other fluids.

Scientists at the University of Central Florida, (Orlando, FL, USA), used specially prepared nanoparticles of iron oxide, coated with a type of sugar called dextran. They looked for specific characteristics of the cholera toxin receptor (GM1) found on cells' surface in the patient's gut, and then they introduced these features to their nanoparticles.

When the magnetic nanoparticles are added to water, blood, or other fluids to be tested, the cholera toxin binds to the nanoparticles in a way that can be easily detected by instruments. The scientists say the test hardware can be turned into portable gear that health care workers could use in the field. The approach also shows promise for treating cholera intoxication.

The use of magnetic relaxation switches is an emerging technology that has been utilized for the sensitive and fast detection of clinically relevant biomolecules, cells, and metabolic activity in complex media. In the present study, the investigators used molecular mimicry to identify by magnetic relaxation and confirm by surface plasmon resonance (SPR) that galactose and dextran interact with CTB. This information has been used to develop selective magnetic relaxation nanoswitches to detect the cholera toxin. Vibrio cholerae produces the toxin that can cause severe diarrhea, which can lead to rapid dehydration and death. Prompt treatment thus is essential, and yet existing tests to diagnose cholera are time-consuming, expensive, and require the use of complex equipment.

Cholera affects more than 200,000 people annually, mainly in developing countries, and causes about 5,000 deaths mainly amongst the infants, children, and the elderly.

Cholera is rampant in Haiti and almost 40 other countries and the development of a fast, simple test to detect the toxin that causes the disease is paramount. The study was published on January 12, 2011, in Bioconjugate Chemistry.

Related Links:

University of Central Florida



Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.